

oligonucleotide 4 to 60 nucleotide long comprising a sequence which is anti-sense to the selected fragment, the second oligonucleotide having an adenosine base content of up to and including about 15%.

REMARKS

THE PENDING CLAIMS

Claims 108-131, 133-134, 146, 148, 151-156, 158-159, 161-173, 178-181, 183-189, 191-193, 195-198 and 200-234 are pending in this case, and no claims are being amended hereby.

THE SPECIFICATION

The present amendments are necessary due to typographical/clerical errors incurred at the time of filing at page 38 and original claim 89. From the context, it may be surmised that in order for an anti-sense oligonucleotide to have an adenosine (A) base at a specific site, the target nucleic acid must have at the site a thymidine (T) if it is DNA, or a uridine (U) if it is RNA.

Further support for these amendments may be found in the same paragraph bridging pages 37 and 38, in the definition of universal bases that are provided for substitution of adenosine (A) bases in the anti-sense oligonucleotide. These universal bases are said to "bind to thymidine (T) but lack the ability to activate adenosine receptors and otherwise may not activate adenosine receptors."

The oligonucleotide made in accordance with this invention is designed to be anti-sense to the selected target segment and, therefore, its content will be up to and including 15% T or U, depending on whether it is a gene target or n RNA target.

The applicant requests consideration of the present amendments to the specification and is providing substitute page 38 for printing purposes.

The Assistant Commissioner is hereby authorized to charge any fees owed, or refund any excess, to PTO Deposit Account No. 50-1728, including a fee for an extension of time that, if needed, is hereby requested.

In view of the foregoing amendments and remarks, the applicants believes that this application is in condition for examination and allowance. Early notice to this respect is solicited.

Respectfully submitted.
EPIGENESIS PHARMACEUTICALS, INC



Viviana Amzel, Ph. D.
Reg. No. 30930
Attorney for the Applicant

July 16, 2001
Date

7 Clarke Drive
Cranbury, NJ 08512
609-409-3035 Ph.
413-845-7530 Fax
Vamzel@epigene.com

s:\legal\00672\Amendment 01-7-16 Supplemental